Actively Recruiting
Personalized Treatment Selection Using Brain Imaging and Clinical Data for Adults with Treatment-Resistant Depression Comparing rTMS and Ketamine
Led by Weill Medical College of Cornell University · Updated on 2026-09-23
27
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Depression is a leading cause of disability worldwide, and many people do not improve with common treatments like antidepressants and talk therapy. This research aims to compare two alternative treatments for people with depression that has not responded to standard therapies repetitive transcranial magnetic stimulation rTMS, a non-invasive brain stimulation, and ketamine, a fast-acting medication. The study focuses on using biological and behavioral markers to predict which treatment might work better for each individual, helping to guide treatment choices more quickly and effectively. Participants will be randomly assigned to receive either rTMS or ketamine. The rTMS treatment involves up to five consecutive days of 10 hourly sessions using intermittent theta burst stimulation applied to the left dorsolateral prefrontal cortex. The ketamine treatment consists of six intravenous sessions over two weeks, with each session delivering a subanesthetic dose of ketamine over 40 minutes. This pilot study will evaluate how practical and acceptable this biomarker-based approach is for patients and whether brain imaging and clinical data can predict treatment response. During the study, participants will undergo assessments including brain imaging and clinical evaluations to measure depression severity and responses to treatment. The main outcome measured is the change in depression severity from baseline to two weeks after treatment using the Hamilton Depression Rating Scale. Additional measures include evaluating the antidepressant selection approach up to eight weeks post-treatment. Participants must be available for the study duration and have access to psychiatric care before, during, and after the trial. Safety monitoring and follow-up assessments will help determine the effectiveness of this personalized treatment strategy.
CONDITIONS
Brief Title
Biomarker-Guided Antidepressant Selection
Research Team
R
Research Coordinator, Interventional Psychiatry Program
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here